A ranar 11 ga Agusta, Cibiyar Kimanta Magunguna (CDE) ta Hukumar Kayayyakin Lafiya ta Ƙasa (NMPA) ta nuna cewa an gabatar da aikace-aikacen InxMed don ƙwayoyin IN10018 don tantance maganin nasara, wanda aka yi niyya don haɗawa da D-1553 don magance ciwon daji na hanji na KRAS G12C wanda ya ci gaba ko kuma ya kamu da cutar kansar hanji (CRC) wanda ya sami aƙalla layuka biyu na magani a baya.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Shaidar WeChat: 17801183037
Email：myimmnet@163.com
Game da Ifebemtinib (IN10018)
Ifebemtinib (IN10018) wani ƙaramin ƙwayar cuta ne da ake amfani da shi ta baki, wanda ke hana FAK, wanda ke da alaƙa mai mahimmanci tare da nau'ikan hanyoyin magani daban-daban. A asibiti, ya nuna haɗin gwiwa tsakanin jiyya da chemotherapy, hanyoyin magani da aka yi niyya, da kuma hanyoyin rigakafi. Zuwa yanzu, an yi wa marasa lafiya sama da 600 magani tare da ingantaccen aminci da juriya.
A taron shekara-shekara na ASCO na 2025, an fitar da sabbin bayanai na asibiti daga gwajin asibiti na Phase Ib/II (NCT06166836; NCT05379946) don kimanta inganci da amincin ifebemtinib (IN10018), wani mai hana adhesion kinase na baki (FAK) tare da garsorasib (D-1533), wani mai hana KRAS G12C na baki, a cikin ƙwayoyin cuta masu canzawa na KRAS G12C.
Bayanan asibiti da aka gabatar a taron shekara-shekara na ASCO na 2025 (Taƙaitaccen Bayani #8629 | Allon Talla #109) sun haɗa da sakamako daga ƙungiyoyi biyu:
Bayanan bin diddigin juriya na ƙungiyar hannu ɗaya a cikin marasa lafiya da ke fama da cutar kansar huhu ta KRAS G12C (wanda ba ƙaramin ƙwayar cuta ba ce) waɗanda suka sami maganin ifebemtinib + garsorasib, ba tare da la'akari da yanayin PD-L1 ba.
Ƙungiyar da bazuwar ta ƙunshi marasa lafiya da aka yi wa magani a baya waɗanda suka kamu da cutar kansar hanji ta KRAS G12C-mutant (CRC) suna kwatanta ifebemtinib+ garsorasib idan aka kwatanta da garsorasib monotherapy.
A cikin ƙungiyar NSCLC, haɗin ifebemtinib da garsorasib, a matsayin tsarin magani na baki biyu, wanda ba shi da chemotherapy, ya nuna fa'ida mai ban sha'awa ta asibiti, gami da yawan amsawa mai yawa da ingantaccen aiki mai ɗorewa, ba tare da la'akari da bayyanar PD-L1 ba, kuma a cikin ƙungiyar CRC, sakamakon ya nuna ingantaccen ƙarin aiki ta ifebemtinib idan aka kwatanta da maganin hana KRAS guda ɗaya.
Muhimman bayanai a cikin NSCLC na farko: Tsarin Baki Biyu Yana Nuna Inganci Mai Dorewa da Fa'idar Rayuwa Mai Fitowa
Ya zuwa ranar 31 ga Maris, 2025, an yi wa marasa lafiya 33 na farko na NSCLC rajista, ba tare da la'akari da yanayin PD-L1 ba, kuma an karɓi haɗin ifebemtinib da garsorasib, tare da matsakaicin bin diddigin watanni 16.0. A baya, kamfanin ya ba da rahoton ƙimar Amsawar Manufofi (ORR) na 90.3% (bayanan da aka gabatar a ESMO 2024). Yanzu an taƙaita bayanan bin diddigin kamar haka:
Tsaka-tsakin rayuwa ba tare da ci gaba ba (mPFS): watanni 22.3
Matsakaicin tsawon lokacin amsawar DOR (mDOR): watanni 19.4
Tsaka-tsakin rayuwa gaba ɗaya (mOS): ba a kai ga cimma shi ba tukuna, tare da babban lanƙwasa na rayuwa mai ɗagawa da faɗi wanda ke nuna fa'ida mai ɗorewa.
Abin lura ne cewa maganin ya nuna inganci mai kyau ba tare da la'akari da yanayin bayyanar PD-L1 ba.
Muhimman Abubuwan da aka Gano a CRC da aka Yi wa Maganin da Aka Yi a Baya: Gwajin da aka Yi Bazuwar Ya Tabbatar da Haɗin gwiwa da KRAS G12Ci
Ya zuwa ranar 21 ga Afrilu, 2025, an yi wa marasa lafiya 36 da aka yi wa magani a baya allurar rigakafin cutar CRC 1:1 don karɓar haɗin ifebemtinib + garsorasib ko garsorasib kaɗai. An yi wa dukkan marasa lafiya kimantawa ta hanyar rediyo kuma an tantance martanin maganin ƙari kuma an taƙaita su kamar haka:
ORR: 44.4% (haɗin gwiwa) idan aka kwatanta da 16.7% (mono)
Yawan rage radadi (DCR): 100.0% (haɗin gwiwa) idan aka kwatanta da 77.8% (na ɗaya)
mPFS: Watanni 7.7 (haɗin gwiwa) idan aka kwatanta da watanni 4.0 (mono)
mOS: ba a kai shi a cikin haɗin gwiwa ba tukuna; an lura da rabuwar farko a cikin lanƙwasa na rayuwa
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Shaidar WeChat: 17801183037
Email：myimmnet@163.com
Lokacin Saƙo: Agusta-13-2025